Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman Represents Kingswood Investments in MIRA Pharmaceuticals, Inc.'s pricing of $8.9 Million Initial Public Offering and Nasdaq Listing

Lucosky Brookman congratulates its client Kingswood Investments, a division of Kingswood Capital Partners, LLC, in its role as the sole bookrunner in the successful initial public offering (IPO) of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). MIRA Pharmaceuticals is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new synthetic THC analog.

MIRA Pharmaceuticals priced its IPO at $7.00 per share, offering 1,275,000 shares of common stock for aggregate gross proceeds of $8.9 million, before deducting underwriting discounts, commissions, and other offering expenses. The company also granted the underwriter a 45-day option to purchase an additional 191,250 shares of common stock at the IPO price, less underwriting discounts and commissions, to cover over-allotments, if any.

The offering is set to close on August 7, 2023, subject to customary closing conditions. In connection with the IPO, MIRA Pharmaceuticals has received approval to list its common stock on the Nasdaq Capital Market, with trading expected to commence on August 3, 2023, under the symbol "MIRA."

MIRA Pharmaceuticals plans to utilize the net proceeds from the IPO to advance its clinical development programs, as well as for working capital and general corporate purposes, demonstrating the company's commitment to its growth and expansion plans.